SCHEMBL675753

SCHEMBL675753

O=C(CSCCCO)c1ccc2[nH]c3nccc(Cl)c3c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 5/20 0.41
PTK6 Q13882 4/20 0.41
UTS2R Q9UKP6 2/20 0.38
ALK Q9UM73 2/20 0.38
AURKB Q96GD4 2/20 0.38
AURKA O14965 1/20 0.38
ROCK2 O75116 3/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CDC7 O00311 1/20 0.35
PLK4 O00444 1/20 0.35
CHEK1 O14757 1/20 0.35
MAPK13 O15264 1/20 0.35
PDPK1 O15530 1/20 0.35
DAPK3 O43293 1/20 0.35
DYRK3 O43781 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3668532 0.85 TLR9 (0.42) ERBB2PTK6UTS2RALKAURKB
SCHEMBL3668046 0.84 ERBB2 (0.41) ERBB2PTK6UTS2RALKAURKB
SCHEMBL3666836 0.83 PKM (0.42) ERBB2PTK6ALKAURKBAURKA
Diethylamine SCHEMBL3668048 0.82 ERBB2 (0.45) ERBB2PTK6UTS2RALKAURKB
SCHEMBL3668527 0.82 ERBB2 (0.42) ERBB2PTK6UTS2RALKAURKB
SCHEMBL676913 0.82 ALDH1A1 (0.38) ERBB2PTK6UTS2RKDM4EALDH1A1
SCHEMBL3668534 0.81 ERBB2 (0.42) ERBB2PTK6UTS2RALKAURKB
SCHEMBL675224 0.80 ALDH1A1 (0.38) KDM4EALDH1A1HPGDHSD17B10GCGR
SCHEMBL675345 0.80 CA1 (0.47) ERBB2PTK6ALKAURKBAURKA
SCHEMBL676353 0.78 RAB9A (0.50) ERBB2PTK6AURKBAURKAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895744-B2 Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) 2014-11-25 US disclosed
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) 2011-11-17 US disclosed
EP-2161271-A1 Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl Università Degli Studi Di Milano - Bicocca (IT) 2010-03-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281862-A1 ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL ALK, BCR, NPM1 ERBB2 156/4885PTK6 2466/4885UTS2R 4708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.